Clinical trials of Chimeric Antigen Receptor T-cell (CAR-T) therapy was conducted globally. Therapy has emerged as a breakthrough in cancer treatment. It has shown promising results on end stage patients, especially in patients of Acute Lymphocytic Leukemia.
Highlights
- CAR-T technology has a remarkable therapeutic potential for cancer patients.
- This technology is not available in India, currently.
Background
BIRAC and DBT have initiated and launched specialised calls and invitation to promote and support development of CAR-T cell technology against cancer and other diseases.
What are the challenges?
CAR-T cell therapy costs rupees 3-4 crore for each patient. Thus, biggest challenge is there to develop this technology in cost-effective manner and make it available patients. Manufacturing of this technology is complex which increases the cost.
First CAR-T cell Therapy
First CAR-T cell Therapy was done by IIT Bombay and cancer care in India at Bone Marrow Transplant unit of Tata Memorial Centre in Mumbai. CAR-T cells were designed and manufactured at Bioscience and Bioengineering (BSBE) department, IIT Bombay. This was also supported by BIRAC-PACE scheme. Now, this therapy will undergo Phase I and II trial of their CAR-T product through National Biopharma Mission.